The market isn't seeing SNTA's true potential. This stock is deeply undervalued at the moment. A true price range it should trade at would be $1.10 - $ 1.75 in the medium term even without any effects of expected positive news. SNTA's merger with Madrigal Pharma
is also being discounted, while in actual fact it's a great combination, the management details would stand testament to that.